Prestige Q2 revenue $289.3M (+4.7% YoY), EPS $1.02; reaffirms FY2023 outlook

Prestige Consumer Healthcare Inc.

2023-Q2 EPS reported $2.11 revenue$566,332,000

Record Q2 revenue $289.3M (+4.7% YoY, +5.5% ex-currency); diluted EPS $1.02, ahead of expectations.
International OTC segment revenue $37.2M (+51.9% YoY) driven by Hydralyte demand.
Reduced debt by $35M; leverage ratio 3.7x; completed $50M share repurchase program.
Reaffirms FY2023 outlook: revenue $1.12-1.13B, diluted EPS $4.18-4.23, FCF $260M+.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Prestige Consumer Healthcare Inc. reported the fiscal quarter and six months ended September 30, 2022 results: revenue $289.3 million, net income $51.0 million, EPS $1.02. Guidance reaffirmed.

Period: the fiscal quarter and six months ended September 30, 2022
Revenue: $289.3 million
Net income: $51.0 million
EPS: $1.02
Guidance: reaffirmed
Result: reported results

Exact text from the filing

herein by reference. --- EX-99.1 (EX-99.1) --- Prestige Consumer Healthcare Inc. Reports Second Quarter Results and Reaffirms Outlook for Fiscal 2023 ◦ Record Revenue of $289.3 Million in Q2 fiscal 2023 increased 4.7% versus Prior Year and 5.5% excluding Currency ◦ Diluted EPS of $1.02 for Q2, ahead of expectations ◦ Reduced Debt by $35 million in Q2 and

View on SEC.gov

Browse all earnings releases →

Prestige Consumer Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001295947-22-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.